Clinical trials · Boston, MA
Advanced or Metastatic Solid Tumors clinical trials in Boston
We’re tracking 418 recruiting advanced or metastatic solid tumors studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT05875168RecruitingPhase 1/Phase 2
Study of DS-3939a for Advanced Solid Tumors
This trial is testing a new drug called DS-3939a for people with advanced solid tumors that have not responded to other treatments. The study has two parts to find the right dose and see how well it works.
Providence, Rhode IslandAges 18 years+ - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Providence, Rhode IslandAges 18 years+ - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Providence, Rhode IslandAges 18–75 - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Providence, Rhode IslandAges 18–99 - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Providence, Rhode IslandAges 18 years+ - NCT06253130RecruitingPhase 1/Phase 2
Study of IMP1734 for Advanced Solid Tumors with HRR Mutations
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
Providence, Rhode IslandAges 18–89 - NCT05317858RecruitingPhase 3
Open the brain’s blood barrier to treat lung cancer brain spots
This trial tests whether using focused ultrasound to temporarily open the brain’s blood barrier—plus standard immune therapy—can better treat non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to help medicines reach the brain tumor spots more effectively, while still using the usual lung cancer treatment.
Providence, Rhode IslandAges 18–100 - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Providence, Rhode IslandAges 18 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Providence, Rhode IslandAges 18 years+ - NCT07446855RecruitingPhase 1/Phase 2
Study of AZD4956 for advanced solid tumors with DNA repair problems
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
Providence, Rhode IslandAges 18–130 - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Providence, Rhode IslandAges 18 years+ - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Providence, Rhode IslandAges 18 years+ - NCT04680377Recruiting
Using gut microbes to predict durvalumab side effects in lung cancer
This study looks at the microbiome (the tiny organisms in your gut) to try to predict who will get side effects from durvalumab after chemoradiation. If you join, your care team will use your microbiome results to help understand toxicity risk and improve future treatment planning.
Providence, Rhode IslandAges 18 years+ - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Providence, Rhode IslandAges 12 years+ - NCT07182591RecruitingPhase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Providence, Rhode IslandAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Providence, Rhode IslandAges 18 years+ - NCT06996782RecruitingPhase 1/Phase 2
Lung cancer study testing new combination treatments
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Providence, Rhode IslandAges 18 years+ - NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Providence, Rhode IslandAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Providence, Rhode IslandAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Providence, Rhode IslandAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Providence, Rhode IslandAges 18 years+ - NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
Providence, Rhode IslandAges 18 years+ - NCT05277168RecruitingPhase 1/Phase 2
Study drug for advanced stomach or pancreatic cancer with Claudin 18.2
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
Providence, Rhode IslandAges 18 years+ - NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Providence, Rhode IslandAges 15 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Research Site · 7 studies
- Rhode Island Hospital · 7 studies
- Women & Infants Hospital of Rhode Island · 3 studies
- Lifespan Cancer Institute · 2 studies
- Brown University
- Brown University Health
- Brown University Health Cancer Institute
- Rhode Island Hospital, Brown University
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Massachusetts.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Boston?
- Yes. We're currently tracking 418 recruiting advanced or metastatic solid tumors studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.